X-Message-Number: 2547 Date: 13 Jan 94 08:17:07 EST From: Paul Wakfer <> Subject: CRYONICS Which Company does What? To: CRYONET Several people and their postings continue to confuse the functions of the four companies cohabiting the research facility (now located in Rancho Cucamonga) which Mike Darwin and I have put together during the last two years. This was made evident by Ben Best's statement in CRYOMSG # 2539: > He was not aware of the nephrotoxicity >of sucrose -- which is, after all, a very recent discovery by >Biopreservation. While Mike Darwin is an eloquent spokesman for the research conducted at our facility and the head of the research team which has conducted the research, it would be wrong to equate Mike with BioPreservation and to assume that BioPreservation does, and has done, all the research conducted at the facility. Presented in order of the company's date of creation, here is a quick description of what each of the four companies does: Cryovita Laboratories, Inc. (formerly Jerry Leaf's company) President: Paul Wakfer Research Director: Mike Darwin Research Consultant: Steve Harris, MD Research Consultant: Greg Fahy, Ph.D. Work during last 2 years: Canine Asanguinous Hypothermic Perfusion Three dogs survived with no permanent deficits after more than five hours of asanguinous perfusion at 3-4 degrees C. (This work was ultimately paid for by 21st Century Medicine, which purchased the rights to this work and has been continuing the experiments since June 1993.) Thus, Ben should have said "a recent discovery of Cryovita Laboratories". Cryovita has been dormant since July of 1993 since it has no funding to pursue its research goals (see below). This is partly because, while 21st Century Medicine traded a large block of shares for the rights to Cryovita's research and will eventually reimburse Cryovita for equipment purchases and for contract research done, this reimbursement has yet to occur because the 21st Century Medicine stock offering failed to raise enough money to reimburse cryovita. Future Research Plans: 1) Brain cryopreservation studies using rabbits and other animals; 2) Optimal Storage Temperature Research. Cryovita's research mandate is: research into the effects of temperatures below 0 degrees C on whole bodies, heads or brains which is related to cryonics. This work is expected to lead to suspended animation of the brain within 5 years. The Director of this research will be Greg Fahy. It was supposed to get started on a small scale with the 21CM reimbursement money, but didn't. We had planned and still do plan to make a stock offering some time this year to raise money to finance this research. BioPreservation, Inc. President and Sole Proprietor: Mike Darwin Consultant: Steve Harris, MD Work during last 2 years: 1) Rental of equipment to Cryovita and 21CM to conduct Canine Asanguinous Hypothermic Perfusion experiments. 2) Preparation for doing all aspects of human cryopreservation from remote standby before legal death to cool-down at dry ice temperature (-79C). 3) Training of team members on both field and operating room aspects of human cryopreservation using two dogs. In order to utilize the dogs in the best way possible, and because Cryovita had not yet commenced any cryopreservation studies (because of lack of funds, see above), the training was not done as a sham run but proceeded all the way, exactly as a human cryopreservation. The dogs are currently sitting in a ultra-low temperature freezer at -90C and will ultimately be studied for the damage effects of freezing. (See Mike Darwin for details.) 21st Century Medicine, Inc. President (absentee): Sandra Russell Business Manager: Paul Wakfer Research Director: Mike Darwin Research Director (for mouse longevity experiments) and Research Consultant (for asanguinous hypothermic perfusion experiments): Steve Harris, MD. Work during the last year: 1) Purchasing and outfitting the facility in Rancho Cucamonga. 2) Continuing the asanguinous hypothermic experiments. 21CM's research mandate involves whole bodies at temperatures above 0 degrees C which is of use to cryonics, life extension and standard medicine. 21CM, if it can get properly capitalized, expects to develop salable products for use in recovery of humans from major bodily damage in remote locations, maximal use of human organs, and minimization of damage due to heart attacks and seizures within about 5 years. Another stock offering is planned and is expected to be presented to the Biotechnology risk capital investment community by late spring of 1994. (We believe that one reason for 21CM's disappointing sale of stock last year was that we relied too much on the cryonics and life extension communities to support the company.) CryoSpan, Inc. President: Paul Wakfer Consultants: Mike Darwin & Brian Wowk, MS This company is the first long-term cryonic care service provider for CryoCare Foundation. Its job will be to accept cryopreserved patients (both humans and companion animals) at -79C and to encapsulate them, cool them down to -196C and hold them safely immersed in liquid nitrogen FOR as long as the organization which has control over the patient desires and pays for such services. Currently, CryoSpan is ready to accept neuro patients. A four-patient whole body dewar is expected to be installed at the end of January. A serious study is under way concerning the feasibility of protecting the dewars from the effects of earthquake and fire by burying them underground. Rate This Message: http://www.cryonet.org/cgi-bin/rate.cgi?msg=2547